Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins

a technology of botulinum toxins and botulinum toxins, applied in the direction of peptidases, peptide/protein ingredients, enzymology, etc., can solve the problems of slow diffusion rate of i>botulinum /i>toxins, improper sterilization and sealing of food containers, etc., to reduce hypersecretion or sweating, reduce muscle spasms, and treat neurologic pain

Inactive Publication Date: 2016-04-28
REVANCE THERAPEUTICS INC
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This invention is about a composition that includes a type of bacteria called botulinum toxin and a carrier made of a special high-charged material. The composition can be applied to the skin to treat things like wrinkles, migraines, or sweating. It can also be injected into facial muscles to achieve a more voluminous effect. The technique uses a special method to deliver the botulinum toxin to the desired area, which helps to achieve the desired effect while minimizing any side effects.

Problems solved by technology

When the horny layer loses its softness and flexibility it becomes rough and brittle, resulting in dry skin.
Their action essentially blocks signals that normally would cause muscle spasms or contractions, resulting in paralysis.
Additionally, it is possible that the larger (greater than about 150 kD molecular weight) botulinum toxin complexes may result in a slower rate of diffusion of the botulinum toxin away from a site of intramuscular injection of a botulinum toxin complex.
Spores of C. botulinum are found in soil and can grow in improperly sterilized and sealed food containers.
Ingestion of the bacteria can cause botulism, which can be fatal.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
  • Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins
  • Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins

Examples

Experimental program
Comparison scheme
Effect test

example 1

Transport of a Botulinum Toxin In Vivo Using a Peptidyl Carrier

[0066]This experiment demonstrates the use of a peptidyl carrier to transport a large complex containing an intact labeled protein botulinum toxin across intact skin after a single time administration relative to controls.

Backbone Selection:

[0067]The positively charged backbone was assembled by conjugating -Gly3Arg7 to polylysine (MW 112,000) via the carboxyl of the terminal glycine to free amines of the lysine side chains at a degree of saturation of 18% (i.e., 18 out of each 100 lysine residues is conjugated to a -Gly3Arg7). The modified backbone was designated “KNR”. The control polycation was unmodified polylysine (designated “K”, Sigma Chemical Co., St. Louis, Mo.) of the same size and from the same lot.

Therapeutic Agent:

[0068]Botox® brand of botulinum toxin A (Allergan) was selected for this experiment. It has a molecular weight of approximately 150,000.

Preparation of Samples

[0069]The botulinum toxin was reconstitu...

example 2

Therapeutic Efficacy of a Topical Botulinum Toxin Preparation with a Peptidyl Carrier

[0077]Example 1 demonstrated that the peptidyl transdermal carrier allowed efficient transfer of botulinum toxin after topical administration in a murine model of intact skin. However, this experiment did not indicate whether the complex protein botulinum toxin was released in a functional form after translocation across skin. The following experiment was thus constructed to evaluate whether botulinum toxin can be therapeutically delivered across intact skin as a topical agent using this peptidyl carrier (again, without covalent modification of the protein).

[0078]The positively charged backbone was again assembled by conjugating -Gly3Arg7 to polylysine (MW 112,000) via the carboxyl of the terminal glycine to free amines of the lysine side chains at a degree of saturation of 18% (i.e., 18 out of each 100 lysine residues is conjugated to a -Gly3Arg7). The modified backbone was designated “KNR”. Contro...

example 3

Therapeutic Efficacy of a Topical Botulinum Toxin Preparation with a Nonpeptidyl Carrier

[0086]This experiment demonstrates the performance of a non-peptidyl carrier in the invention.

Methods:

Backbone Selection:

[0087]The positively charged backbone was assembled by conjugating -Gly3Arg7 to polyethyleneimine (PEI) MW 1,000,000 via the carboxyl of the terminal glycine to free amines of the PEI side chains at a degree of saturation of 30% (i.e., 30 out of each 100 lysine residues is conjugated to a -Gly3Arg7). The modified backbone was designated “PEIR” to denote the large nonpeptidyl carrier. Control polycation was unmodified PEI (designated “PEI”, Sigma Chemical Co., St. Louis, Mo.) of the same size and from the same lot. The same botulinum toxin therapeutic agent was used as in example 1.

[0088]Botulinum toxin was reconstituted from the Botox product according to the manufacturer's instructions. In each case, an excess of polycation was employed to assemble a final complex that had an ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and other conditions that may be treated with a botulinum toxin, particularly paralysis of subcutaneous, and most particularly, facial, muscles, by topically applying an effective amount of the botulinum toxin and carrier, in conjunction, to the subject's skin or epithelium. Kits for administration are also described.

Description

[0001]This application is a continuation under 35 U.S.C §120 of U.S. patent application Ser. No. 13 / 846,899, filed on Mar. 18, 2013, now U.S. Pat. No. 9,211,248, which is a continuation under 35 U.S.C §120 of U.S. patent application Ser. No. 10 / 591,732, filed on Sep. 26, 2007, now U.S. Pat. No. 8,398,997, which is a national stage filing under 35 U.S.C. §371(c) of International PCT Application No. PCT / US05 / 07524, filed on Mar. 3, 2005, which claims benefit of U.S. Provisional Patent Application No. 60 / 550,015, filed on Mar. 3, 2004, the contents of each of which are hereby incorporated by reference herein in their entirety.BACKGROUND OF THE INVENTION[0002]Skin protects the body's organs from external environmental threats and acts as a thermostat to maintain body temperature. It consists of several different layers, each with specialized functions. The major layers include the epidermis, the dermis and the hypodermis. The epidermis is a stratifying layer of epithelial cells that ove...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/48A61K47/48
CPCA61K38/4893C12Y304/24069A61K47/48176A61K47/48315A61K47/34C07K2319/10A61K47/58A61K47/645A61K9/0014A61K39/08
Inventor DAKE, MICHAEL D.WAUGH, JACOB M.
Owner REVANCE THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products